Pharmaceutical

STAT+: Senate working group proposes 340B reforms

A group of senators released a draft of proposed legislation to clarify controve...

STAT+: AI therapy and ICU training: A first look at hea...

Exclusive: Apple works with Cedars-Sinai , Boston Children’s Hospital to develop...

STAT+: Pharmalittle: We’re reading about opioid settlem...

A division of the Publicis Groupe and Hikma Pharmaceuticals reached separate set...

What makes a drug a blockbuster — or a cautionary tale?

Though Aduhelm's last rights had arguably already been read before Biogen retire...

Opinion: Can Arena Bioworks upend the traditional scien...

Can Arena Bioworks upend the traditional scientific research model in the U.S.?

Texas Medical Board under pressure to define emergency ...

Two high-profile abortion supporters filed a petition seeking to clarify the gro...

Promising red-light myopia treatment for children is ra...

The benefits of a red-light laser treatment for myopia may come at the risk of c...

Opinion: Medicare has different standards than the FDA....

Medicare has different standards than the FDA. That’s how it should be.

As England’s virus hospitalisations surge flu vaccines ...

England evaluates vaccine procurement and pandemic preparedness, whilst Moderna’...

Scottish company secures £4.2m to advance 3D-printed mi...

Carcinotech has gained funding to enter the North American market with the compa...

LimmaTech secures funding for vaccine technology develo...

LimmaTech announced the closing of a second round of its Series A financing, sec...

Biosyngen’s liver cancer therapy receives fast track de...

The US Food and Drug Administration (FDA) has granted fast track designation (FT...

Sanofi backs development of Graviton’s treatments for s...

Graviton Bioscience has secured a strategic investment from Sanofi to propel the...

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric di...

The US FDA has granted rare paediatric disease (RPD) designation for Tyra Biosci...

Keytruda remains Merck & Co’s biggest 2023 success stor...

Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setb...

BMS reports 2% revenue loss in 2023 after Revlimid gene...

Bristol Myers Squibb has reported a 2% revenue decrease from 2022 as it focuses ...